达比加群甲酯杂质 | 771459-37-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 达比加群甲酯杂质
• 英文名称: KE5D5QJ3SP
• 英文别名: methyl 3-[[2-[(4-carbamimidoylanilino)methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate
• CAS: 771459-37-1
• 化学式: C₂₆H₂₇N₇O₃
• 分子量: 485.5
• InChiKey: YNXUXWCCKIZGCU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  36
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  139
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• [EN] NOVEL REFERENCE MARKERS OF DABIGATRAN ETEXILATE<br/>[FR] NOUVEAUX MARQUEURS DE RÉFÉRENCE D'ÉTÉXILATE DE DABIGATRAN
  申请人：ALEMBIC PHARMACEUTICALS LTD

  公开号：WO2013024394A1

  公开（公告）日：2013-02-21

  A new method of obtaining chemically pure and pharmaceutically acceptable Dabigatran Etexilate or its pharmaceutical acceptable salt having purity at least about 99% is provided, wherein the content of Dabigatran Etexilate individual impurity is less than 0.03-0.15% as measured by HPLC. A method of removing specific impurities that are generated either due to the intrinsic instability of Dabigatran Etexilate or in process of its preparation is provided too.

  提供了一种获得化学纯和药学可接受的达比加群胺乙酯或其药学可接受的盐的新方法，其纯度至少为约99％，其中达比加群胺乙酯个体杂质的含量小于0.03-0.15％，通过HPLC测量。还提供了一种去除特定杂质的方法，这些杂质是由达比加群胺乙酯的固有不稳定性或制备过程中产生的。
• PROCESS FOR THE PREPARATION OF BENZIMIDAZOLE DERIVATIVES AND ITS SALTS
  申请人：MSN Laboratories Limited

  公开号：EP2649060B1

  公开（公告）日：2017-04-05
• [EN] AN IMPROVED PROCESS FOR THE PREPARATION OF DABIGATRAN ETEXILATE MESYLATE AND ITS INTERMEDIATES THEREOF<br/>[FR] PROCÉDÉ PERFECTIONNÉ POUR LA PRÉPARATION D'ETEXILATE MÉSYLATE DE DABIGATRAN ET DE SES INTERMÉDIAIRES
  申请人：RAO DAVULURI RAMAMOHAN

  公开号：WO2014009966A2

  公开（公告）日：2014-01-16

  An improved process for the preparation of Dabigatran Etexilate Mesylate and the processes for the preparation of Dabigatran single prodrug and Dabigatran Etexilate are described in this invention
• [EN] A PROCESS FOR PREPARATION OF DABIGATRAN ETEXILATE MESYLATE AND INTERMEDIATES THEREOF<br/>[FR] PROCÉDÉ DE PRÉPARATION DE DABIGATRAN ÉTÉXILATE MÉSYLATE ET DE SES INTERMÉDIAIRES
  申请人：MEGAFINE PHARMA P LTD

  公开号：WO2015128875A2

  公开（公告）日：2015-09-03

  The present invention relates to an improved process for the preparation of Dabigatran etexilate and its acid addition salts thereof, wherein the said process substantially eliminates the potential impurities. The present invention also relates to an intermediate of Dabigatran etexilate and process for preparation thereof.